The OS of patients did not differ between molecular subtypes; however, the OS of patients with mesenchymal tumors is distinctly bimodal and largely determined by MGMT methylation status (Fig. 1A and Supplementary Fig. 1B). The gene discussed is MGMT; the disease is mesenchymal cell neoplasm.